Stock Overview
| Snowflake Score | |
|---|---|
| Valuation | -1/6 |
| Future Growth | -1/6 |
| Past Performance | -1/6 |
| Financial Health | -1/6 |
| Dividends | -1/6 |
Price History & Performance
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| 4015 | SA Pharmaceuticals | SA Market | |
|---|---|---|---|
| 7D | 4.4% | -1.4% | -1.5% |
| 1Y | n/a | 0.8% | -6.4% |
Return vs Industry: Insufficient data to determine how 4015 performed against the SA Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 4015 performed against the SA Market.
Price Volatility
| 4015 volatility | |
|---|---|
| 4015 Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in SA Market | 7.8% |
| 10% least volatile stocks in SA Market | 2.5% |
Stable Share Price: 4015 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4015's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 1,255 | Tarek Youssef Hosni | n/a |
Fundamentals Summary
| 4015 fundamental statistics | |
|---|---|
| Market cap | ر.س9.60b |
| Earnings (TTM) | ر.س310.97m |
| Revenue (TTM) | ر.س1.19b |
31.2x
P/E Ratio8.2x
P/S RatioIs 4015 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4015 income statement (TTM) | |
|---|---|
| Revenue | ر.س1.19b |
| Cost of Revenue | ر.س433.89m |
| Gross Profit | ر.س751.54m |
| Other Expenses | ر.س440.57m |
| Earnings | ر.س310.97m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.44 |
| Gross Margin | 63.40% |
| Net Profit Margin | 26.23% |
| Debt/Equity Ratio | 0% |
How did 4015 perform over the long term?
See historical performance and comparison